BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) are inoperable and highly resistant tumors to chemotherapy and irradiation. DIPG has the worst prognosis among all pediatric brain tumors and the overwhelming majority of patients die within 6-18 months after diagnosis. METHODS: We retrospectively reviewed the charts of six DIPG patients treated with chemoradiotherapy (daily carboplatin and oral etoposide in five patients and temozolomide in one patient) followed by maintenance chemotherapy consisting of irinotecan, temozolomide, and bevacizumab at our institution between January 2007 until December 2007. RESULTS: Event-free survival (EFS) and overall survival (OS) were 10.4 ± 3.08 and 14.6 ± 3.55 months, respectively. Side effects in the patients included hypertension in two, abdominal cramping and diarrhea in four, and neutropenia in five patients. CONCLUSIONS: This augmented regimen was associated with increased but tolerable toxicity and a modest increase in EFS and OS when compared with published literature in patients with DIPG (median EFS and OS of 6.1 and 9.6 months, respectively). More effective therapies are desperately needed.
BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) are inoperable and highly resistant tumors to chemotherapy and irradiation. DIPG has the worst prognosis among all pediatric brain tumors and the overwhelming majority of patients die within 6-18 months after diagnosis. METHODS: We retrospectively reviewed the charts of six DIPGpatients treated with chemoradiotherapy (daily carboplatin and oral etoposide in five patients and temozolomide in one patient) followed by maintenance chemotherapy consisting of irinotecan, temozolomide, and bevacizumab at our institution between January 2007 until December 2007. RESULTS: Event-free survival (EFS) and overall survival (OS) were 10.4 ± 3.08 and 14.6 ± 3.55 months, respectively. Side effects in the patients included hypertension in two, abdominal cramping and diarrhea in four, and neutropenia in five patients. CONCLUSIONS: This augmented regimen was associated with increased but tolerable toxicity and a modest increase in EFS and OS when compared with published literature in patients with DIPG (median EFS and OS of 6.1 and 9.6 months, respectively). More effective therapies are desperately needed.
Authors: Erin E Crotty; Sarah E S Leary; J Russell Geyer; James M Olson; Nathan E Millard; Aimee A Sato; Ralph P Ermoian; Bonnie L Cole; Christina M Lockwood; Vera A Paulson; Samuel R Browd; Richard G Ellenbogen; Jason S Hauptman; Amy Lee; Jeffrey G Ojemann; Nicholas A Vitanza Journal: J Neurooncol Date: 2020-06-16 Impact factor: 4.130
Authors: Trent R Hummel; Ralph Salloum; Rachid Drissi; Shiva Kumar; Matthew Sobo; Stewart Goldman; Ahna Pai; James Leach; Adam Lane; David Pruitt; Mary Sutton; Lionel M Chow; Laurie Grimme; Renee Doughman; Lori Backus; Lili Miles; Charles Stevenson; Maryam Fouladi; Mariko DeWire Journal: J Neurooncol Date: 2015-12-01 Impact factor: 4.130
Authors: Jonathan Metts; Brittany Harrington; Emad Salman; Scott M Bradfield; Jennifer Flanary; Maua Mosha; Ernest Amankwah; Stacie Stapleton Journal: Childs Nerv Syst Date: 2022-03-08 Impact factor: 1.475
Authors: Z Gokce-Samar; P A Beuriat; C Faure-Conter; C Carrie; S Chabaud; L Claude; F Di Rocco; C Mottolese; A Szathmari; C Chabert; D Frappaz Journal: Childs Nerv Syst Date: 2016-07-05 Impact factor: 1.475